Sano blog | patient engagement (2)

rare disease patient engagement

Rare disease drug development requires designing for access from day one

Rare disease innovation has accelerated in recent years, particularly in cell and gene therapy (CGT). Yet for drug developers, one challenge remains persistent:...

rare disease patient engagement

Barriers to long-term follow-up in cell and gene therapy

Cell and gene therapy (CGT) programs are committing to 10-15 years of follow-up – often without the infrastructure to support it. FDA guidance for certain gene ...

patient recruitment patient engagement

From click to randomization: What truly predicts trial success?

Digital recruitment has become a standard part of clinical trial execution. Sponsors invest heavily in online outreach, patient referrals, and awareness campaig...

Effective site enablement in precision medicine

patient recruitment patient engagement

What strong site enablement really looks like: Lessons from Sano’s site expert

Trial sponsors often assume that site enablement is largely complete once a trial launches. Feasibility assessments, training materials, and startup timelines a...

thought leadership rare disease patient engagement

Redefining accessibility in cell and gene therapies

Cell and gene therapy continues to advance across a growing number of rare genetic conditions. As more of these therapies move closer to the clinic, a central t...

Communicating with clinical trial participants

patient recruitment patient engagement

Closing the communication gap: A sponsor’s guide to building patient trust and retention

Participation in clinical trials can be burdensome and disruptive. In addition to practical inconveniences and discomfort, participants may have to take time of...

Behind the scenes with a patient navigator lead

patient recruitment patient engagement

Behind the scenes at Sano: Navigating the patient journey

Advocating for patients is one of the core pillars of Sano’s mission. Our approach to clinical trials is patient-centered and entails deep and meaningful engage...

Q&A with Kendall Davis Sano's Head of Clinical Engagement

rare disease patient engagement

Overcoming rare disease trial hurdles: Q&A with Sano's Head of Clinical Engagement

Rare disease trials are among the most challenging to design and execute. Patient populations are small and hard to reach, and personal and disease-related burd...

DPHARM panel on clinical trial patient matching

patient recruitment patient engagement

Building trust in clinical trial patient matching: Takeaways from DPHARM 2025

At this year’s DPHARM conference, Sano’s VP of Commercial, Ben Jackson, joined a panel on clinical trial patient matching moderated by a clinical expert from No...

patient recruitment patient engagement

Q2 2025 product update: New features for seamless trial execution

At Sano Genetics, our mission is to make clinical research in precision medicine faster, more inclusive, and more efficient. In our Q2 2025 product webinar, we ...

Clinical research blog

Rare disease drug development requires designing for access from day one

Barriers to long-term follow-up in cell and gene therapy

From click to randomization: What truly predicts trial success?

What strong site enablement really looks like: Lessons from Sano’s site expert

Redefining accessibility in cell and gene therapies

Closing the communication gap: A sponsor’s guide to building patient trust and retention

Behind the scenes at Sano: Navigating the patient journey

Overcoming rare disease trial hurdles: Q&A with Sano's Head of Clinical Engagement

Building trust in clinical trial patient matching: Takeaways from DPHARM 2025

Q2 2025 product update: New features for seamless trial execution

Join the email list